DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study

NodeGuardian · 2026-03-09T13:58:24+00:00

DBV Technologies reported positive Phase 3 VITESSE study results for the VIASKIN® Peanut Patch, showing significant efficacy and safety. The company aims to submit a Biologics License Application to the FDA, highlighting the patch's potential for treating peanut allergies in children.

NodeGuardian

2026-03-09 13:58:24

Abstract generation in progress

DBV Technologies announced positive data from its Phase 3 VITESSE study of the VIASKIN® Peanut Patch, presented at the AAAAI 2026 Annual Meeting. The study showed significant efficacy and a good safety profile, with 83% of children increasing their eliciting dose and 46.6% meeting treatment responder criteria. The company plans to submit a Biologics License Application to the FDA in the first half of this year, banking on the patch’s potential as a non-invasive treatment for peanut-allergic children.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.